October 12, 2023:
Virtu Financial LLC, an institutional investor, has recently acquired a new stake in Regeneron Pharmaceuticals, Inc. This information was revealed in Virtu Financial’s latest filing with the Securities and Exchange Commission (SEC), known as Form 13F. According to the filing, Virtu Financial purchased 9,431 shares of Regeneron Pharmaceuticals’ stock during the second quarter. The total value of this investment amounted to approximately $6,776,000.
Regeneron Pharmaceuticals now makes up about 0.5% of Virtu Financial LLC’s portfolio. This places Regeneron Pharmaceuticals as the company’s 23rd largest holding. The decision to invest in Regeneron Pharmaceuticals highlights Virtu Financial’s confidence in the biopharmaceutical industry and its potential for growth.
The most recent quarterly earnings report from Regeneron Pharmaceuticals was released on August 3rd of this year. The report showed that the company reported earnings per share (EPS) of $10.24 for the quarter. This exceeded analysts’ consensus estimates by $1.76 per share. In comparison to the same period last year, when Regeneron Pharmaceuticals earned $9.77 per share, there was a positive increase in earnings.
Regeneron Pharmaceuticals also revealed a return on equity (ROE) of 19.19%, indicating that it is effectively generating profits with the shareholder’s investment. Furthermore, the company boasted a net margin of 33.93%, which demonstrates its ability to efficiently convert revenues into profits.
During the quarter under review, Regeneron Pharmaceuticals recorded revenue of $3.16 billion. This surpassed analysts’ expectations of $3.02 billion and represented a year-over-year increase of 10.5%. These results reflect consistent growth within the company and indicate its strong performance in delivering value to shareholders.
Sell-side analysts have projected that Regeneron Pharmaceuticals, Inc. will achieve earnings per share of 35.38 for the current fiscal year on average. This estimate suggests that Regeneron Pharmaceuticals will continue its upward trajectory and maintain its profitability.
In conclusion, Virtu Financial LLC’s recent acquisition of a stake in Regeneron Pharmaceuticals, Inc. highlights the company’s confidence in the future growth potential of the biopharmaceutical industry. Regeneron Pharmaceuticals’ strong quarterly earnings report, with higher-than-expected EPS and robust revenue growth, solidifies its position as a valuable investment opportunity. As the fiscal year progresses, all eyes are now on Regeneron Pharmaceuticals to see if it can exceed expectations and further demonstrate its success in this demanding market.
[bs_slider_forecast ticker=”JNJ”]
Regeneron Pharmaceuticals, Inc.: Ownership Changes, Executive Transactions, and Analyst Ratings
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biopharmaceutical company, has seen several changes in its ownership positions among hedge funds in recent quarters. In the second quarter, ICICI Prudential Asset Management Co Ltd raised its holdings in Regeneron Pharmaceuticals by 6.5%, acquiring an additional 45 shares which brought their total holdings to 733 shares valued at $527,000. Similarly, Kovack Advisors Inc. increased their holdings by 16.9% during the first quarter, adding 55 shares to bring their total value to $312,000. Stratos Wealth Partners LTD and Lindbrook Capital LLC also reported increases of 13.6% and 8.2%, respectively.
Notably, Creative Planning acquired an additional 350 shares during the last quarter, raising its holdings by 6.1%. This increased their total ownership to 6,117 shares valued at $4,395,000.
Overall, institutional investors and hedge funds currently own approximately 84.15% of Regeneron Pharmaceuticals’ outstanding stock.
On October 12th, REGN traded down $1.23 to reach $833.73 per share on NASDAQ. The company had a trading volume of 131,490 shares compared to its average volume of 575,074 shares. With a market capitalization of $90.51 billion and a price-to-earnings ratio of 21.96, Regeneron Pharmaceuticals continues to be an attractive investment option.
The stock’s fifty-day simple moving average stands at $818.48 while its two-hundred-day simple moving average is $782.23.
Regeneron Pharmaceuticals has demonstrated both a strong performance in the market and stability over the past year; it reached a yearly low of $668 per share and a high of $847.50 per share.
Furthermore, pertinent executive transactions have taken place recently within the company. On August 23rd, CFO Robert E. Landry sold 223 shares at an average price of $844.00, reflecting a total value of $188,212.00. Following this sale, the chief financial officer now owns 31,699 shares valued at $26,753,956.
In a concurrent transaction on August 22nd, EVP Neil Stahl sold 11,665 shares of Regeneron Pharmaceuticals’ stock at an average price of $840.98 per share for a total transaction value of $9,810,031.70. The executive vice president now holds 53,100 shares in the company valued at $44,656,038.
These transactions were disclosed in accordance with Securities and Exchange Commission regulations and can be accessed through its website.
According to recent information released by the SEC about insider trades within Regeneron Pharmaceuticals over the last three months; corporate insiders have sold a total of 33,209 shares valued at $27,841,391.
Despite these insider sales activity being significant in scale and representing around 8.83% of the company’s stock holdings by insiders; it is important to note that overall ownership by institutional investors remains high.
Numerous equities research analysts have weighed in on Regeneron Pharmaceuticals’ prospects as well. Argus recently increased their price target from $825 to $920 and issued a “buy” rating for the company on September 15th.
Similarly, VNET Group reaffirmed a “downgrade” rating on shares of Regeneron Pharmaceuticals on June 28th while Robert W. Baird reduced their price target from $800 to $760 on the same date.
Canaccord Genuity Group upgraded their rating from “hold” to “buy” and raised their price target from $720 to $992 on August 21st.
Lastly, Cantor Fitzgerald maintained a “neutral” rating and set a price target of $800 in the market on September 21st.
Overall, Regeneron Pharmaceuticals currently holds an average rating of “Moderate Buy” and a consensus price target of $898.04 based on data from Bloomberg.
Regeneron Pharmaceuticals remains a top player in the biopharmaceutical industry, attracting interest from institutional investors and hedge funds alike. With its impressive market capitalization and solid financial performance, the company is poised for continued growth and success in the future.
